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 Highlights 
● Sexual minority females are at an elevated risk for substance use. 
● Bisexual females particularly appear to be at a high risk for substance use. 
● Bisexual females should be prioritized in adolescent substance use prevention. 
 
 
Abstract 
Background: Health sciences researchers are beginning to understand the differing experiences 
and health risks among sexual minority subgroups (i.e., those who describe themselves as 
homosexual/gay/lesbian, bisexual, or unsure/questioning). Such research can promote the 
allocation of resources to high-risk groups and the development of interventions tailored to their 
needs. The present study extends this line of research to substance use among adolescents. 
Methods: The lifetime and/or past 30-day alcohol, tobacco, cigarette, e-cigarette, marijuana, 
prescription drug, and illicit drug use of sexual minority and heterosexual adolescents was 
analyzed using data from the 2015 National Youth Risk Behavior Survey. Controlling for 
confounders, separate logistic regression models were fit for each substance use outcome. A 
simulation-based strategy was employed to report adjusted risk ratios for each substance use 
outcome for each sexual minority subgroup. 
Results: Sexual minority females, particularly bisexual females, were at an elevated risk for 
substance use. For example, compared to heterosexual females, sexual minority females were 
1.35 (95%CI 1.16-1.56) times more likely to have used a substance in the past 30 days, and 
bisexual females had an even further elevated risk ratio (RR: 1.48, 95%CI 1.28-1.69).  
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Conclusions: Studying the variance among sexual minority subgroups will help practitioners, 
advocates, and policymakers identify high risk subgroups. In the case of substance use, this study 
suggests sexual minority females, particularly bisexual females, should become a target 
population for prevention and other interventions. The study conducts post-hoc analyses on 
secondary data, and so these results should be verified in more targeted studies. 
Keywords: sexual minority; substance use; lesbian; gay; bisexual; questioning; alcohol; 
marijuana; prescription drugs 
 1. Introduction 
 It is now understood that differential stresses and pressures are endured by lesbian, gay, 
and bisexual, and questioning (LGBQ) adolescents (Drabble and Trochi, 2005; Hatzenbeuler, 
2014). Consequently, it is now necessary to evaluate the differential health behaviors of these at-
risk populations (Institute of Medicine, 2011; Meyer and Frost, 2013; Caputi et al., 2017). 
Conditions for sexual minority adolescents have changed considerably within the past decade 
(Russell et al., 2010; Perone, 2015; SCOTUS, 2015; Homma et al., 2016), and new risk estimates 
that take account for the diversity of sexual minority adolescents – including both sex and 
orientation identity – are necessary to discern the needs of these high-risk groups.  
 Intragroup variance among adolescent substance use has seldom been explored in recent 
years. The most comprehensive previous analysis of intragroup variance among LGBQ 
adolescent drug use comes from a meta-analysis of 18 studies conducted by Marshal et al. 
(2008). In this study, the authors find that bisexuality and female sex are significant, positive 
modifiers on the relative risk of LGBQ adolescent substance use. The meta-analysis by Marshal 
et al. (2008) is useful as it draws upon results from several different kinds of samples including 
high-risk groups, schools, and the general population. However, because it relies on several 
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different studies, it compiles different gradations of substance use (30-day, past-year, etc.) into a 
singular outcome of substance use. Further, it may rely too heavily on populations willing to ask 
their samples about adolescent sexual orientation as opposed to data representing a national 
sampling frame. Further, the meta-analysis uses data that is now, in some cases, two decades old, 
which was a different era for LGBQ sentiment in the United States. 
 Where intragroup variance among LGBQ adolescent substance use has been recently 
explored – namely, within the study of tobacco use – it has yielded significant and actionable 
findings. For example, several studies (Austin et al., 2004; Emory et al., 2016; Johnson et al., 
2016) have found that female sexual minority subgroups, and particularly bisexual females, have 
higher odds of tobacco use in adolescence than their heterosexual counterparts. While the most 
comprehensive of these studies to date (Dai, 2017) uses odds ratios, making inference regarding 
relative risk difficult or impossible (Caputi, 2017), it is a signal that tobacco use interventions 
designed for adolescents should treat sexual minority females as a priority population. 
 Though there are few representative and contemporary studies examining the substance 
use risks of sexual minority adolescents, there is a thriving body of literature for sexual minority 
adults. In several studies conducted over several years, researchers have shown that sexual 
minority adults are more likely to exhibit several risk behaviors. Since the field has developed, 
some researchers have examined the intragroup variance within sexual minority adults (Cochran 
and Mays, 2016). For example, several studies have found that sexual minority women, and 
particularly bisexual women, are at an elevated risk for several health risk behaviors (e.g., 
McCabe et al., 2009; Blosnich et al., 2014; Kerr et al., 2014). Indeed, some research has shown 
differential trends within the sexual minority population in which the risk difference between 
sexual minority males and heterosexual males is shrinking, and the same risk difference for 
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females is growing (Cochran and Mays, 2017). These trends over time are useful not only in 
describing which groups continue to be at high risk but also in diagnosing contributors to health 
risks among sexual minorities. Stressors change differentially for different subgroups, and so 
researchers may hypothesize which stressors are most significant from related changes in health 
behaviors. Importantly, research into intragroup variance among sexual minority adults’ health 
behaviors has inspired action in support of the highest-risk subgroups (Cochran and Mays, 2016; 
Drabble and Trochi, 2005). It is reasonable that similar exploration among sexual minority 
adolescents may also yield significant findings and action on behalf of the high-risk subgroups.  
 The burden alcohol, tobacco, marijuana, non-medical prescription drug, and illicit drug 
use place on young people’s livelihoods and society’s health care resources is substantial 
(Whiteford et al., 2013), and a better understanding of at-risk populations can justify both the 
allocation of additional resources to help those communities and the development of specifically-
tailored programs and services (Zaza et al., 2016). The minority stressors that are known to cause 
elevated high risks among sexual minorities (Meyer and Frost, 2013; Saewyc, 2016) could 
covary among sex and orientation identity for adolescents. If they do, that finding could promote 
action to support the highest-needs groups and research into how that disparity could be 
ameliorated. Therefore, an exploration of the risks of substance use among the diversity of sexual 
minority subgroups is justified. 
 2. Methods 
 2.1 Data  
 In this study, data from the public-use file of the 2015 National Youth Risk Behavior 
Survey (NYRBS) was leveraged. This file included the confidential responses of 15,624 
adolescents. 
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 The NYRBS is a biannual paper survey administered in schools using a three-stage 
cluster sample design of counties, schools within counties, and classrooms within schools to 
achieve a nationally-representative sample of American high school students (Brener et al., 
2013). For the 2015 iteration, the NYRBS had an overall response rate of 60% (69% school 
response rate * 86% participant response rate). 
 The 2015 NYRBS is an approved protocol by the Centers for Disease Control and 
Prevention’s Institutional Review Board, which required appropriate consent from parents and 
assent from youth participants. Because the data was previously existing, publicly available, and 
entirely de-identified, the current study did not require further review under HHS regulation 
45CFR 46.101(b)(4), which was confirmed by the University of Pennsylvania Institutional 
Review Board. 
 2.2 Dependent variable 
 The reported use of alcohol, cigarettes, e-cigarettes, marijuana, and prescription drugs 
were assessed. Tobacco use altogether (incorporating use of cigarettes, cigars, smokeless 
tobacco, and/or e-cigarette use) and illicit drug use altogether (incorporating use of cocaine, 
ecstasy, hallucinogens, heroin, inhalants, marijuana, methamphetamine, prescription drugs, 
steroids, and/or synthetic marijuana) were also studied. It is noted that some use of marijuana 
captured within this measure may be medically motivated and, therefore, permitted under state 
law. However, because all marijuana use is illegal under federal law (i.e., U.S. Controlled 
Substances Act), and only approximately 0.35% of children age 12-17 reported using medical 
marijuana in the past year in the 2015 National Survey on Drug Use and Health, marijuana use is 
included in illicit drug use. Aggregate measures were developed for any and poly-drug (2 or 
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more drugs) use for both the 30-day timeframe and the lifetime time-frame, based upon data 
availability for each timeframe. 
 Substance use outcomes were selected/developed based upon having an overall 
prevalence conducive to executing reasonably precise analyses within each of the sexual 
minority subgroups. That is, drug-specific data was available for cigar, smokeless tobacco, 
cocaine, ecstasy, hallucinogens, heroin, inhalants, methamphetamine, steroids, and synthetic 
marijuana use, but because each of these substance use outcomes are rare, they were aggregated 
in order to support reasonably precise analyses. Prescription drug misuse refers to reported use of 
a prescription medication without a prescription. E-cigarette use refers to reported use of an 
electronic vapor device, although it is not explicitly stated in the questionnaire that the electronic 
vapor device was used to vape liquid nicotine. 
 2.3 Independent variables 
 Each participants’ sexual minority subgroup was determined both by sexual orientation 
and sex. Sex was evaluated with the question, “what is your sex?” with possible responses, 
“female” and “male” (respondents can only choose one). 
 Sexual orientation was measured in the YRBS through both orientation identity, i.e., how 
the respondent identifies, and sex of previous sexual contacts. These two measures showed some 
discordance. Because the sample size is larger for orientation, orientation comprises a more 
actionable group (i.e., it is much easier to observe a person’s orientation than their sexual 
history), and including only children with a sexual history may bias the sample, sexual 
orientation rather than sex of past sexual contacts is used. This practice is in line with other 
studies of this sample (Dai, 2017; Zaza et al., 2016) 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 Sexual orientation was evaluated with the question, “which of the following best 
describes you?” with possible responses, “heterosexual (straight),” “gay or lesbian,” “bisexual,” 
and “not sure”. Sex was evaluated with the question “What is your sex?” with possible responses 
“female” and “male”. From these questions, participants were then categorized into sexual 
orientation subgroups as “heterosexual” (88.8% total, 84.5% female (N=6105), 93.1% male 
(N=6779)), “gay or lesbian” (2.0% total, 2.0% female (N=167), 2.0% male (N=154)), “bisexual” 
(6.0% total, 9.8% female (N=734), 2.4% male (N=178)), or “not sure,” i.e., questioning (3.2% 
total, 3.7% female (N=296), 2.6% male (N=199)).  
 2.4 Covariates 
 Controls were added for the participants’ sex (male/female), age (continuous), 
race/ethnicity (7 categories: 1. American Indian/Alaska Native, 2. Asian, 3. Black, 4. Hispanic, 
5. Native Hawaiian/Pacific Islander, 6. White, and 7. Multiple Races (non-Hispanic)), English 
proficiency (1. very well or well or 2. not well or not well at all), and average academic grades 
(1. B or higher or 2. C or lower). These covariates were chosen to account for known differences 
in substance use behaviors among those with different sexes, ages, races, acculturation, and 
school/community connectedness (respectively). 
 2.5 Statistical analysis 
 First, descriptive analyses were conducted to describe prevalence rates of each of the 
substance use outcomes by sexual minority subgroup. Then, the data were analyzed to yield the 
relative risk of sexual minority adolescents compared with their heterosexual peers. Separate 
logistic regression models were fit for each of the substance use outcomes. Because odds ratios 
can be misleading for common outcomes (Davies et al., 2016), risk ratios are reported. Risk 
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ratios represent the ratio of estimated prevalence among sexual minority adolescents to the 
estimated prevalence of their heterosexual counterparts.  
 Risk ratios were computed by simulating 10,000 vectors of model coefficients based 
upon random draws from each logistic regression model’s variance-covariance matrix and then 
estimating a distribution of predicted probabilities for an individual in that sexual minority 
subgroup with covariates held at their mean values (King et al., 2010). The mean of this 
distribution of risk ratio is interpreted as the point estimate for the risk ratio, and the 2.5th and 
97.5th percentile are interpreted as the 95% confidence interval. All analyses were conducted in 
R version 3.4.1 and were adjusted for the NYRBS’s complex survey design using the “survey” 
package (Lumley, 2004). 
 3. Results  
 3.1 Absolute prevalence 
 The prevalence of substance use among sexual minority adolescents was higher than that 
among heterosexual peers (Table 1). For example, 83.4% (95%CI 79.7%-87.1%) of sexual 
minority females reported using a substance in their lifetime compared to 71.0% (95%CI 66.1%-
75.8%) for heterosexual females, and 55.0% (95%CI 50.5%-59.6%) of sexual minority females 
reported use of a substance within 30 days of taking the survey compared to 40.2% (95%CI 
36.0%-44.4%) for heterosexual females. 
 3.2 Adjusted analyses  
 In adjusted analyses, sexual minority males did not show a clear elevated risk of 
substance use relative to heterosexual males; however, sexual minority females were at a 
significantly higher risk for substance use relative to heterosexual females (Table 2). For 
example, sexual minority females were significantly more likely to report using alcohol (RR: 
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1.23, 95%CI 1.07-1.4), tobacco (RR: 1.99, 95%CI 1.32-2.88), and marijuana (RR: 1.71, 95%CI 
1.41-2.05) in the past 30 days. Further, sexual minority females were significantly more likely to 
report using alcohol (RR: 1.17, 95%CI 1.07-1.29), cigarettes (RR: 1.88, 95%CI 1.59-2.22), 
marijuana (RR: 1.59, 95%CI 1.4-1.79), prescription drugs (RR: 1.7, 95%CI 1.41-2.03), and illicit 
drugs (RR: 2.13, 95%CI 1.52-2.9) in their lifetime.  
 Among sexual minority females, only bisexual females showed a clear elevated risk of 
reporting recent or lifetime substance use. Bisexual females were at an elevated risk for 
substance use in all 11 studied substances. In contrast, lesbian and questioning females were at 
an elevated risk for only four substances, and only for two substance use outcomes (i.e., lifetime 
cigarette use and lifetime prescription drug use) were all female sexual minority subgroups at an 
elevated risk. That is, there was insufficient evidence to suggest that lesbian or questioning 
females were at significantly elevated risks of substance use generally.  
 3.3 Aggregate measures 
 Risk ratios for aggregate measures (any use of substance or use of two or more 
substances) were significant among sexual minority females, and particularly bisexual females, 
but were not significant among sexual minority males. 
 4. Discussion 
 Sexual minority females, specifically bisexual females, are at a greater risk for substance 
use (including tobacco use, alcohol use, marijuana use, non-medical prescription drug use, and 
illicit drug use) compared to their heterosexual counterparts. The NYRBS data is insufficient to 
conclude that sexual minority males, lesbian females, and questioning females are at an elevated 
risk for substance use.  
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 This study contributes to the growing body of literature (Marshal et al., 2008) 
documenting how relative risk for substance use among sexual minority adolescents is changing 
and developing as steps are taken to improve stressors for LGBQ adolescents. Further, previous 
research has shown that, among sexual minority adults, bisexual females are at a particularly 
high risk for drug use (McCabe et al., 2009; Cochran and Mays, 2017). This study’s findings 
show that this pattern is also present among a nationally representative sample of adolescents. 
 The findings of this study are significant for two reasons. First, female sexual minority 
adolescents appear to be a high priority population. Because females are less likely to use most 
drugs (SAMHSA, 2014), and fewer females enter substance use disorder treatment programs 
(TEDS, 2012), female adolescents may be discounted in both the development of interventions 
and the allocation of intervention resources. There is evidence that the etiology of drug use is 
different in girls and boys and that only a small subset of evidence-based prevention programs 
are effective for girls (Kumpfer et al., 2009). Future research may investigate, if current drug 
prevention programs are indeed ineffective for girls, whether this may compound the substance 
use risks of sexual minority adolescents. 
 Second, the bisexual identity group is often not taken as seriously as gay or lesbian 
adolescents in a variety of arenas (Alarie and Gaudet, 2013). Our findings suggest that bisexual 
adolescents, particularly bisexual females, were at a particularly high risk of substance use. 
Therefore, advocates and practitioners should recognize the substance use risks of bisexual 
adolescents and begin to explore the needs of that community. For example, researchers may 
consider the risk and protective factors for substance use within this specific subgroup and 
whether current intervention and treatment programs are tailored to meet the needs of that 
community. 
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 There are several limitations to this study. Conducting subgroup analyses of sexual 
minorities presents significant challenges (Yusuf et al., 1991), and readers are advised to 
interpret findings judiciously. Ideally, researchers should conduct a survey that is representative 
of sexual minorities with an a priori hypothesis that a difference in sexual minority subgroup 
exists for a specific outcome (in this case, substance use; see Stall et al., 2001). However, 
conducting such a survey – a survey with a prospectively stated hypothesis to be tested and 
targeting a representative population of sexual minority adolescents – would likely be 
prohibitively resource-intensive. Instead, we perform post hoc analyses of existing secondary 
data from a survey that was not specifically designed to test whether significant intragroup 
variance exists. Such subgroup analyses can be misleading; conducting several tests for different 
subgroups, which inherently have diminished sample sizes, may result in spurious findings. 
These smaller sample sizes have significant implications for the current study. For example, 
because there were significantly fewer males than females reporting sexual minority status, the 
confidence intervals of analyses for females was typically wider than comparable analyses for 
females. Further, only a subset of all substances evaluated on the NYRBS were analyzed because 
analysis of rarer substances by sexual minority subgroup would have insufficient sample sizes. 
Overall, these findings should be treated as hypothesis generating, requiring replication in future 
studies with more well-suited datasets. Even with the limitations of post-hoc secondary data 
analysis, however, this analysis is important. These findings represent contemporary responses to 
a survey that pulls from adolescents in different ethnic/racial groups located across the country. 
Indeed, the same dataset used in this study (i.e., 2015 NYRBS) has been used to evaluate similar 
questions in previous studies (e.g., Dai, 2017; Caputi et al., 2017). 
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 To improve the state of the literature, further study, particularly surveys with 
prospectively-stated hypotheses targeting the sexual minority population, should be conducted to 
confirm the current study’s findings. In the immediate future, analyses of pooled data from 
several years of NYRBS datasets will have sufficient sample size to suggest a broader range of 
hypotheses with greater precision. Eventually, surveys that prospectively investigate intragroup 
variance in sexual minority adolescent substance use with large (and ideally representative) 
samples of sexual minority participants should be conducted. 
 Two broader limitations of the NYRBS are noted: first, the overall response rate of the 
NYRBS was low (60%), which may have an impact on generalizability. Second, although the 
survey employed confidentiality protections, there is a risk that sexual minority children may 
have been unwilling to admit their identity. 
 The results presented in this paper serve not only as a call to action to provide better and 
perhaps tailored services to sexual minority adolescents but also to provide an idea of which 
sexual minority subgroups may be most at risk. Before, females and bisexuals were likely to be 
marginalized from substance use prevention programming; however, our results imply sexual 
minority females, particularly bisexual females, should be prioritized in the fight against 
adolescent substance use.  
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Figures and table 
 
 
Table 1. Prevalence of Substance Use Among Lesbian, Gay, Bisexual, Questioning, and Heterosexual Adolescents 
Male Adolescents 
      
  
  
Sexual Minority (N=531) Gay (N=154) Bisexual (N=178) 
Substance 
Timefram
e 
Unweighte
d N 
Weighted 
Prevalenc
e 95%CI 
Unweighte
d N 
Weighted 
Prevalenc
e 95%CI 
Unweighte
d N 
Weighted 
Prevalenc
e 
95%C
I 
Alcohol 
Past 30 
Days 436 37.3% 
31.4%-
43.2% 110 36.1% 
22.8%-
49.5% 158 39.0% 
29.8%
-
48.2% 
Alcohol Lifetime 482 64.3% 
57.2%-
71.3% 135 69.5% 
57.6%-
81.4% 165 61.3% 
51.9%
-
70.8% 
Tobacco 
Use 
Past 30 
Days 438 18.9% 
14%-
23.8% 118 13.8% 
4.5%-
23% 155 15.6% 
7.5%-
23.6% 
Cigarettes 
Past 30 
Days 464 17.3% 
12.5%-
22.2% 124 14.5% 
5.6%-
23.4% 165 16.2% 
8.3%-
24.2% 
Cigarettes Lifetime 431 40.8% 
31.9%-
49.7% 117 40.8% 
25.7%-
55.9% 154 44.5% 
35.1%
-
53.9% 
Vaping 
Past 30 
Days 505 26.4% 
21%-
31.9% 145 22.7% 
14.5%-
30.9% 170 23.7% 
14.4%
-
32.9% 
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Vaping Lifetime 490 39.6% 
33.8%-
45.4% 139 41.1% 
26.3%-
55.8% 166 39.4% 
28.2%
-
50.5% 
Marijuana 
Past 30 
Days 485 27.2% 
21%-
33.4% 130 28.0% 
16.7%-
39.3% 169 23.8% 
14%-
33.5% 
Marijuana Lifetime 476 40.7% 
31.1%-
50.3% 126 47.3% 
29.4%-
65.3% 169 38.1% 
26.5%
-
49.7% 
Prescriptio
n Drugs Lifetime 522 28.7% 
22.2%-
35.3% 151 37.2% 
24.9%-
49.6% 175 23.2% 
13.4%
-
33.1% 
Illicit 
Drugs Lifetime 331 21.8% 
14.9%-
28.7% 81 22.5% 
9.6%-
35.5% 122 17.0% 
9.8%-
24.2% 
Any Drug 
Use 
Past 30 
Days 385 43.0% 
35.4%-
50.6% 96 40.0% 
24.8%-
55.2% 142 45.1% 
34.4%
-
55.9% 
Any Drug 
Use Lifetime 314 71.8% 
64.2%-
79.5% 76 83.2% 
74.5%-
91.9% 120 67.8% 
55.3%
-
80.3% 
Poly-Drug 
Use 
Past 30 
Days 385 26.7% 
20%-
33.4% 96 21.3% 
10.9%-
31.7% 142 26.7% 
16.9%
-
36.5% 
Poly-Drug 
Use Lifetime 314 54.6% 
48.7%-
60.6% 76 53.9% 
36.1%-
71.7% 120 54.2% 
43.2%
-
65.3% 
         
  
Female Adolescents 
       
  
  
Sexual Minority (N=1197) Lesbian (N=167) Bisexual (N=734) 
Substance 
Timefram
e 
Unweighte
d N 
Weighted 
Prevalenc
e 95%CI 
Unweighte
d N 
Weighted 
Prevalenc
e 95%CI 
Unweighte
d N 
Weighted 
Prevalenc
e 
95%C
I 
Alcohol 
Past 30 
Days 1044 39.6% 
35.5%-
43.7% 135 37.7% 
27.2%-
48.2% 644 42.5% 
36.7%
-
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48.3% 
Alcohol Lifetime 1145 74.9% 
70.8%-
79% 152 68.6% 
59.3%-
77.9% 713 81.4% 
76.6%
-
86.2% 
Tobacco 
Use 
Past 30 
Days 1107 15.7% 
12.2%-
19.2% 149 15.0% 
7.2%-
22.8% 680 18.2% 
14%-
22.5% 
Cigarettes 
Past 30 
Days 1136 18.2% 
14.2%-
22.1% 153 16.2% 
7.3%-
25.2% 697 21.5% 
16.9%
-
26.2% 
Cigarettes Lifetime 1059 50.2% 
45.1%-
55.4% 144 48.6% 
37.3%-
59.8% 655 54.2% 
48.1%
-
60.3% 
Vaping 
Past 30 
Days 1180 29.4% 
25.9%-
32.9% 162 30.7% 
21.5%-
39.8% 726 31.6% 
26.7%
-
36.5% 
Vaping Lifetime 1155 55.9% 
51.7%-
60.1% 156 56.9% 
48.6%-
65.1% 715 59.3% 
54.3%
-
64.3% 
Marijuana 
Past 30 
Days 1163 31.6% 
28.6%-
34.5% 161 37.1% 
26.7%-
47.5% 714 33.7% 
29.6%
-
37.8% 
Marijuana Lifetime 1159 53.9% 
50.1%-
57.7% 161 58.8% 
47.9%-
69.7% 713 56.8% 
52.6%
-
60.9% 
Prescriptio
n Drugs Lifetime 1184 25.1% 
22.3%-
27.8% 165 28.0% 
20.6%-
35.4% 725 26.1% 
23.2%
-29% 
Illicit 
Drugs Lifetime 848 21.5% 
17.9%-
25% 113 21.1% 
11.7%-
30.6% 538 24.0% 
19.4%
-
28.7% 
Any Drug 
Use 
Past 30 
Days 974 55.0% 
50.5%-
59.6% 125 50.9% 
40.1%-
61.8% 596 60.5% 
54.5%
-
66.5% 
Any Drug Lifetime 820 83.4% 79.7%- 107 76.8% 67.1%- 523 89.6% 86.2%
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Use 87.1% 86.6% -
93.1% 
Poly-Drug 
Use 
Past 30 
Days 974 36.2% 
31.8%-
40.6% 125 37.8% 
27.3%-
48.2% 596 39.8% 
33.5%
-
46.1% 
Poly-Drug 
Use Lifetime 820 71.3% 
66.4%-
76.2% 107 67.3% 
57.2%-
77.3% 523 77.5% 
72.3%
-
82.8% 
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 Table 1 Continued 
Male Adolescents 
     
 
  
Questioning (N=199) Heterosexual (N=6779) 
Substance Timeframe 
Unweighted 
N 
Weighted 
Prevalence 95%CI 
Unweighted 
N 
Weighted 
Prevalence 95%CI 
Alcohol 
Past 30 
Days 168 36.4% 
28.1%-
44.7% 6159 32.0% 
30.2%-
33.8% 
Alcohol Lifetime 182 63.6% 
54.3%-
72.9% 6579 61.6% 
59.2%-
64% 
Tobacco 
Use 
Past 30 
Days 165 25.7% 
15.6%-
35.7% 6320 15.8% 
13.7%-
18% 
Cigarettes 
Past 30 
Days 175 20.3% 
11.2%-
29.4% 6513 11.5% 
9.8%-
13.1% 
Cigarettes Lifetime 160 37.0% 
25.6%-
48.4% 5974 33.5% 
30.4%-
36.7% 
Vaping 
Past 30 
Days 190 31.7% 
19.2%-
44.2% 6706 25.4% 
22.7%-
28.2% 
Vaping Lifetime 185 38.7% 
27.7%-
49.7% 6602 46.5% 
43.2%-
49.9% 
Marijuana 
Past 30 
Days 186 29.8% 
20.9%-
38.7% 6659 23.2% 
20.1%-
26.2% 
Marijuana Lifetime 181 38.8% 
28.6%-
49.1% 6590 40.2% 
36.9%-
43.6% 
Prescription 
Drugs Lifetime 196 27.2% 
18.1%-
36.2% 6707 17.0% 
15.4%-
18.7% 
Illicit 
Drugs Lifetime 128 25.5% 
15%-
36% 4831 15.0% 
13.3%-
16.7% 
Any Drug 
Use 
Past 30 
Days 147 42.7% 
32.7%-
52.6% 5772 44.2% 
41.6%-
46.8% 
Any Drug 
Use Lifetime 118 68.6% 
57%-
80.1% 4673 71.3% 
68.7%-
73.9% 
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Poly-Drug 
Use 
Past 30 
Days 147 30.1% 
19.9%-
40.4% 5772 29.0% 
26.4%-
31.5% 
Poly-Drug 
Use Lifetime 118 55.5% 
44.2%-
66.8% 4673 52.6% 
48.6%-
56.5% 
       
 
Female Adolescents 
    
 
  
Questioning (N=296) Heterosexual (N=6105) 
Substance Timeframe 
Unweighted 
N 
Weighted 
Prevalence 95%CI 
Unweighted 
N 
Weighted 
Prevalence 95%CI 
Alcohol 
Past 30 
Days 265 33.2% 
25.4%-
41% 5621 32.3% 
28%-
36.5% 
Alcohol Lifetime 280 60.6% 
51.4%-
69.7% 5974 63.8% 
59.7%-
67.9% 
Tobacco 
Use 
Past 30 
Days 278 9.5% 
5%-
14.1% 5792 7.7% 
6%-
9.3% 
Cigarettes 
Past 30 
Days 286 10.5% 
5.6%-
15.5% 5942 7.9% 
6%-
9.7% 
Cigarettes Lifetime 260 40.5% 
33.2%-
47.8% 5458 27.1% 
22.3%-
31.9% 
Vaping 
Past 30 
Days 292 22.9% 
17.1%-
28.6% 6038 21.0% 
18.8%-
23.3% 
Vaping Lifetime 284 46.4% 
38%-
54.9% 5963 41.4% 
37.4%-
45.4% 
Marijuana 
Past 30 
Days 288 23.3% 
18.3%-
28.4% 6063 17.8% 
15.2%-
20.4% 
Marijuana Lifetime 285 44.0% 
36.2%-
51.8% 6016 34.4% 
30.3%-
38.5% 
Prescription 
Drugs Lifetime 294 20.9% 
15.1%-
26.6% 6064 13.8% 
12.4%-
15.1% 
Illicit 
Drugs Lifetime 197 14.8% 
10.6%-
19% 4421 10.0% 
7.9%-
12.1% 
Any Drug 
Use 
Past 30 
Days 253 43.8% 
36.2%-
51.5% 5324 40.2% 
36%-
44.4% 
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Any Drug 
Use Lifetime 190 69.8% 
61.9%-
77.8% 4320 71.0% 
66.1%-
75.8% 
Poly-Drug 
Use 
Past 30 
Days 253 27.0% 
21%-
33% 5324 22.5% 
19.4%-
25.7% 
Poly-Drug 
Use Lifetime 190 56.5% 
47.2%-
65.7% 4320 49.7% 
44.3%-
55.1% 
 
Caption: Risk ratios for each substance use outcome compared to heterosexual peers of the same sex, i.e., gay males were compared 
to heterosexual males and lesbian females were compared to heterosexual females, are presented. The risk ratios are based upon data 
from the NYRBS and are adjusted for the NYRBS complex survey design. Tobacco use includes cigarette, cigar, smokeless tobacco, 
and e-cigarette use. Prescription drug use refers only to use not recommended by a healthcare professional. Illicit drug use includes 
cocaine, ecstasy, hallucinogens, heroin, inhalants, marijuana, methamphetamine, prescription drugs, steroids and synthetic marijuana 
use. Lifetime aggregate measures (i.e., lifetime any drug use and lifetime poly-drug use) account for all drug use outcomes that were 
measured at the lifetime timeframe. The NYRBS contains the responses of 15,624 adolescents. Among these responses, 921 did not 
report their sexual orientation, and 118 did not report their sex. After list wise deletion for sex and/or sexual orientation, the relevant 
sample size is 14,612.  
 
 
 
 
Table 2. Relative Risk of Substance Use among Lesbian, Gay, Bisexual, and Questioning Adolescents 
Male Adolescents 
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Sexual Minority 
(N=531) 
Gay 
(N=154) 
Bisexual 
(N=178) 
Questioning 
(N=199) 
Substance Timeframe RR 95%CI RR 95%CI RR 95%CI RR 95%CI 
Alcohol 
Past 30 
Days 1.18 
0.92-
1.46 1.23 
0.67-
1.91 1.09 
0.78-
1.44 1.24 
0.85-
1.67 
Alcohol Lifetime 1.06 0.9-1.21 1.22 
0.99-
1.4 0.9 
0.71-
1.09 1.09 
0.9-
1.28 
Tobacco 
Use 
Past 30 
Days 0.88 
0.53-
1.35 0.65 
0.22-
1.48 0.79 
0.42-
1.34 1.22 
0.61-
2.11 
Cigarettes 
Past 30 
Days 1.22 
0.71-
1.93 1.07 
0.41-
2.20 1.32 
0.69-
2.22 1.31 
0.62-
2.39 
Cigarettes Lifetime 1.17 
0.84-
1.55 0.94 
0.48-
1.51 1.33 
0.94-
1.75 1.18 
0.82-
1.59 
Vaping 
Past 30 
Days 0.97 0.7-1.29 0.7 
0.41-
1.08 0.93 
0.5-
1.52 1.23 
0.75-
1.82 
Vaping Lifetime 0.87 
0.72-
1.04 0.86 
0.5-
1.26 0.89 
0.63-
1.17 0.88 
0.59-
1.20 
Marijuana 
Past 30 
Days 1.12 0.8-1.55 1.04 
0.58-
1.63 1.05 
0.67-
1.52 1.27 
0.82-
1.83 
Marijuana Lifetime 1.02 0.8-1.26 1.1 
0.65-
1.57 0.96 
0.66-
1.32 1.02 
0.72-
1.34 
Prescription 
Drugs Lifetime 1.52 1.06-2.1 1.97 
1.13-
3.04 1.29 
0.66-
2.16 1.45 
0.93-
2.13 
Illicit 
Drugs Lifetime 1.42 
0.93-
2.04 1.67 
0.80-
2.88 1.17 
0.68-
1.83 1.54 
0.88-
2.44 
Any Drug 
Use 
Past 30 
Days 1.05 
0.82-
1.30 1.01 
0.51-
1.57 1.06 
0.74-
1.4 1.07 
0.77-
1.39 
Any Drug 
Use Lifetime 1.02 
0.89-
1.13 1.18 
1.01-
1.3 0.93 
0.73-
1.1 0.98 
0.8-
1.15 
Poly-Drug 
Use 
Past 30 
Days 0.96 
0.72-
1.24 0.84 
0.37-
1.52 0.97 
0.69-
1.29 1.07 
0.68-
1.56 
Poly-Drug 
Use Lifetime 1.05 
0.92-
1.18 1.01 
0.61-
1.39 1.04 
0.82-
1.27 1.08 
0.78-
1.38 
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Female Adolescents 
      
  
  
Sexual Minority 
(N=1,197) 
Lesbian 
(N=167) 
Bisexual 
(N=734) 
Questioning 
(N=296) 
Substance Timeframe RR 95%CI RR 95%CI RR 95%CI RR 95%CI 
Alcohol 
Past 30 
Days 1.23 
1.07-
1.40 1.03 
0.62-
1.51 1.29 
1.04-
1.59 1.16 
0.87-
1.5 
Alcohol Lifetime 1.17 
1.07-
1.29 1.03 
0.82-
1.23 1.26 
1.14-
1.38 0.98 
0.84-
1.12 
Tobacco 
Use 
Past 30 
Days 1.99 
1.32-
2.88 1.68 0.79-3 2.34 
1.75-
3.06 1.21 
0.58-
2.19 
Cigarettes 
Past 30 
Days 2.25 
1.52-
3.22 1.84 
0.89-
3.26 2.74 
2.09-
3.52 1.14 
0.61-
1.93 
Cigarettes Lifetime 1.88 
1.59-
2.22 1.58 
1.02-
2.24 2.04 
1.7-
2.44 1.57 
1.15-
2.05 
Vaping 
Past 30 
Days 1.36 
1.12-
1.65 1.43 
0.93-
2.04 1.44 
1.18-
1.72 1.12 
0.79-
1.5 
Vaping Lifetime 1.35 
1.19-
1.51 1.22 
0.97-
1.49 1.43 
1.26-
1.6 1.18 
0.94-
1.43 
Marijuana 
Past 30 
Days 1.71 
1.41-
2.05 1.53 
0.96-
2.23 1.87 
1.58-
2.19 1.38 
0.93-
1.95 
Marijuana Lifetime 1.59 1.4-1.79 1.47 
1.03-
1.93 1.7 
1.5-
1.92 1.34 
0.97-
1.75 
Prescription 
Drugs Lifetime 1.7 
1.41-
2.03 1.58 
1.02-
2.32 1.77 
1.52-
2.03 1.59 
1.08-
2.2 
Illicit 
Drugs Lifetime 2.13 
1.52-
2.90 1.62 
0.77-
2.87 2.41 
1.88-
3.03 1.62 
1.06-
2.36 
Any Drug 
Use 
Past 30 
Days 1.35 
1.16-
1.56 1.12 
0.79-
1.47 1.48 
1.28-
1.69 1.13 
0.87-
1.39 
Any Drug 
Use Lifetime 1.15 
1.08-
1.23 1.02 
0.84-
1.18 1.22 
1.15-
1.31 1.01 
0.88-
1.13 
Poly-Drug 
Use 
Past 30 
Days 1.62 1.3-2.00 1.48 
0.93-
2.16 1.72 
1.44-
2.02 1.40 
1.09-
1.76 
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Poly-Drug 
Use Lifetime 1.40 
1.27-
1.54 1.24 
0.99-
1.49 1.51 
1.36-
1.68 1.17 
0.92-
1.41 
 
Caption: Risk ratios for each substance use outcome compared the sexual minority subgroup’s use to heterosexual peers of the same 
sex, i.e., gay males were compared to heterosexual males and lesbian females were compared to heterosexual females. The risk ratios 
are based upon data from the NYRBS and are adjusted for the NYRBS complex survey design. Tobacco use includes cigarette, cigar, 
smokeless tobacco, and e-cigarette use. Prescription drug use refers only to use not recommended by a healthcare professional. Illicit 
drug use includes cocaine, ecstasy, hallucinogens, heroin, inhalants, marijuana, methamphetamine, prescription drugs, steroids and 
synthetic marijuana use. Lifetime aggregate measures (i.e., lifetime any drug use and lifetime poly-drug use) account for all drug use 
outcomes that were measured at the lifetime timeframe. Risk ratios are computed using simulations based upon separate logistic 
regressions for each outcome and sexual orientation subgroup. The NYRBS contains the responses of 15,624 adolescents. Among 
these responses, 921 did not report their sexual orientation, and 118 did not report their sex. After list wise deletion for sex and/or 
sexual orientation, the relevant sample size is 14,612. The N’s correspond to the number of respondents in each sexual orientation 
subgroup; there were 6779 heterosexual males, and 6105 heterosexual females in the comparison groups. 
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